Published in J Urol on June 01, 1982
Role of Th1-stimulating cytokines in bacillus Calmette-Guérin (BCG)-induced macrophage cytotoxicity against mouse bladder cancer MBT-2 cells. Clin Exp Immunol (2006) 1.03
Interleukin-10 inhibits Mycobacterium bovis bacillus Calmette-Guérin (BCG)-induced macrophage cytotoxicity against bladder cancer cells. Clin Exp Immunol (2010) 0.92
Prostaglandin E2 down-regulates viable Bacille Calmette-Guérin-induced macrophage cytotoxicity against murine bladder cancer cell MBT-2 in vitro. Clin Exp Immunol (2002) 0.90
The establishment of a growth-controllable orthotopic bladder cancer model through the down-regulation of c-myc expression. Oncotarget (2016) 0.75
Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J Urol (1992) 4.79
Isolation of a human prostate carcinoma cell line (DU 145). Int J Cancer (1978) 4.04
Quality of life: radical prostatectomy versus radiation therapy for prostate cancer. J Urol (1995) 2.80
Development of immunity in human severe primary T cell deficiency following haploidentical bone marrow stem cell transplantation. J Immunol (1986) 2.11
Incidence, etiology, location, prevention and treatment of positive surgical margins after radical prostatectomy for prostate cancer. J Urol (1998) 1.88
Small cell carcinoma of the bladder and prostate. Urology (1995) 1.81
Results of a multicenter trial using the BTA test to monitor for and diagnose recurrent bladder cancer. J Urol (1995) 1.71
De novo muscle invasive bladder cancer: is there a change in trend? J Urol (2001) 1.54
Sampling of radical prostatectomy specimens. How much is adequate? Am J Clin Pathol (1994) 1.51
Prostatectomy tissue for research: balancing patient care and discovery. Am J Clin Pathol (1998) 1.48
Transitional cell carcinoma of the prostate. J Urol (1991) 1.47
The accuracy of urinary cytology in daily practice. Cancer (1999) 1.46
Prognostic significance of changes in prostate-specific markers after endocrine treatment of stage D2 prostatic cancer. Cancer (1992) 1.44
Positive surgical margins with radical retropubic prostatectomy: anatomic site-specific pathologic analysis and impact on prognosis. Urology (1999) 1.44
Does pericapsular lignocaine reduce pain during transrectal ultrasonography-guided biopsy of the prostate? BJU Int (2003) 1.38
Academic anatomic pathology--a perspective. Mod Pathol (1996) 1.38
Patients' choice of treatment in stage D prostate cancer. Urology (1989) 1.34
Pathology of androgen deprivation therapy in prostate carcinoma. A comparative study of 173 patients. Cancer (1995) 1.34
Histologic changes in prostate carcinomas treated with leuprolide (luteinizing hormone-releasing hormone effect). Distinction from poor tumor differentiation. Cancer (1994) 1.33
Tumor-associated hyaluronic acid: a new sensitive and specific urine marker for bladder cancer. Cancer Res (1997) 1.28
The histogenesis of clear cell adenocarcinoma of the lower urinary tract. Case series and review of the literature. Hum Pathol (1996) 1.26
Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. Zoladex Prostate Study Group. Urology (1995) 1.23
Urinary hyaluronic acid and hyaluronidase: markers for bladder cancer detection and evaluation of grade. J Urol (2000) 1.22
Rationale for intensive intravesical chemotherapy for superficial bladder cancer. J Urol (1980) 1.21
Urinary cytology and bladder cancer. The cellular features of transitional cell neoplasms. Cancer (1984) 1.21
Comparison of digital rectal examination and biopsy results with the radical prostatectomy specimen. J Urol (1999) 1.18
Positive surgical margins with radical prostatectomy: detailed pathological analysis and prognosis. Urology (1996) 1.18
Update on bladder neck preservation during radical retropubic prostatectomy: impact on pathologic outcome, anastomotic strictures, and continence. Urology (1998) 1.17
Urothelial susceptibility to tumor cell implantation: influence of cauterization. Cancer (1980) 1.15
Heterotransplantation of a human prostatic adenocarcinoma cell line in nude mice. Cancer Res (1977) 1.14
Complications of advanced prostate cancer. Urology (1999) 1.13
Pneumonia and Hong Kong influenza: a prospective study of the 1968-1969 epidemic. Am J Med Sci (1971) 1.13
Outcome after radical prostatectomy with a pretreatment prostate biopsy Gleason score of >/=8. BJU Int (2003) 1.13
Local anesthesia for ultrasound guided prostate biopsy: a prospective randomized trial comparing 2 methods. J Urol (2001) 1.09
Phase I-II study of mitomycin C topical therapy for low-grade, low stage transitional cell carcinoma of the bladder: an interim report. Cancer Treat Rep (1980) 1.09
Pathologic changes associated with androgen deprivation therapy for prostate cancer. Cancer (1991) 1.08
The nested variant of transitional cell carcinoma: an aggressive neoplasm with innocuous histology. Mod Pathol (1996) 1.08
Intravesical and systemic chemotherapy of murine bladder cancer. Cancer Res (1977) 1.07
Free-riding and the prisoner's dilemma: problems in funding economic analyses of phase III cancer clinical trials. J Clin Oncol (1995) 1.07
Efficacy of targeted supradose cisplatin and concomitant radiation therapy for advanced head and neck cancer: the Memphis experience. Int J Radiat Oncol Biol Phys (1997) 1.05
Ileal conduit exfoliative cytology in the diagnosis of recurrent cancer. J Urol (1972) 1.05
Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone. Cancer (1983) 1.04
The effect of mitomycin C on superficial bladder cancer. J Urol (1981) 1.03
Quality of life 12 months after radical prostatectomy. Br J Urol (1995) 1.02
Safety and efficacy of an implantable leuprolide delivery system in patients with advanced prostate cancer. J Urol (2000) 1.01
Renal disease after mitomycin C therapy. Cancer (1981) 1.00
Improved detection of recurrent bladder cancer using the Bard BTA stat Test. Urology (1997) 1.00
Bond strength and rupture properties of some soft denture liners. J Oral Rehabil (1992) 0.99
Pneumocystis carinii antigenemia in adults with malignancy, infection, or pulmonary disease. J Clin Microbiol (1984) 0.98
Current bladder tumor tests: does their projected utility fulfill clinical necessity? J Urol (2001) 0.98
Prostate cancer after heart transplantation. J Urol (1995) 0.97
The significance of colonic mucosa (intestinal metaplasia) involving the urinary tract. Cancer (1987) 0.97
Characterization of a human prostate adenocarcinoma cell line (DU 145) as a monolayer culture and as a solid tumor in athymic mice. Prog Clin Biol Res (1980) 0.97
Classification of premalignant urothelial abnormalities. A Delphi study of the National Bladder Cancer Collaborative Group A. Pathol Annu (1982) 0.97
Susceptibility of urothelium to neoplastic cellular implantation. Urology (1975) 0.96
Myocarditis in young military personnel. Herpes simplex, trichinosis, meningococcemia, carbon tetrachloride, and idiopathic fibrous and giant cell types. Am Heart J (1967) 0.96
The pains of love: hemoperitoneum following sexual intercourse. JAMA (1986) 0.96
Papillomavirus structural antigens in condyloma acuminatum of the male urethra. J Urol (1983) 0.96
Spontaneous metastasis of cells of the human prostate carcinoma cell line PC-3 in athymic nude mice. J Urol (1982) 0.96
Oncogene expression in prostate cancer: Dunning R3327 rat dorsal prostatic adenocarcinoma system. Prostate (1988) 0.95
Efficacy of targeted chemoradiation and planned selective neck dissection to control bulky nodal disease in advanced head and neck cancer. Arch Otolaryngol Head Neck Surg (1999) 0.95
Selecting initial therapy for bladder cancer. Cancer (1987) 0.95
Treatment of invasive bladder cancer by cisplatin and radiation in patients unsuited for surgery. JAMA (1987) 0.95
A comparison of cisplatin and the combination of cisplatin and cyclophosphamide in advanced urothelial cancer. A National Bladder Cancer Collaborative Group A Study. Cancer (1983) 0.94
Transitional cell neoplasms of the urinary bladder. Can biologic potential be predicted from histologic grading? Cancer (1987) 0.94
Signet ring cell carcinoma of a pulled-through sigmoid colon mimicking a primary invasive bladder tumor: case report and review of the literature. Urology (2000) 0.94
Active surveillance for low-risk prostate cancer: knowledge, acceptance and practice among urologists. Prostate Cancer Prostatic Dis (2011) 0.94
Prophylaxis of bladder tumor implantation. Intravesical and systemic chemotherapy. Urology (1976) 0.93
Carcinoma of the rete testis: case report and review of the literature. J Urol (1993) 0.92
Epithelioid leiomyoma of the bladder: an unusual cause of voiding symptoms. Urology (1998) 0.92
Immunohistochemical evidence of the existence and localization of aromatase in human prostatic tissues. Prostate (1992) 0.92
Histopathological effects of androgen deprivation in prostatic cancer. Semin Urol Oncol (1996) 0.92
Medical, life-style, and occupational risk factors for prostate cancer. Prostate (1987) 0.92
Cytology in the diagnosis and followup of transitional cell carcinoma of the urothelium: a review with a case series. J Urol (1976) 0.92
Comparison of goserelin and leuprolide in combined androgen blockade therapy. Urology (1998) 0.91
The use of cell salvage during radical retropubic prostatectomy: does it influence cancer recurrence? BJU Int (2003) 0.91
C-type virus particles in human urogenital tumours after heterotransplantation into nude mice. Br J Cancer (1979) 0.90
Prognostic significance of urine cytology on initial follow-up after intravesical mitomycin C for superficial bladder cancer. Cancer (1986) 0.90
Finite element analysis of fixed prostheses attached to osseointegrated implants. Quintessence Int (1990) 0.90
Evidence for depressed humoral immunity to Pneumocystis carinii in homosexual males, commercial plasma donors, and patients with acquired immunodeficiency syndrome. J Clin Microbiol (1987) 0.90
Quality of life and psychosocial status in stage D prostate cancer. Zoladex Prostate Cancer Study Group. Qual Life Res (1992) 0.90
IgA nephropathy. A comparative study of the clinicopathologic features in children and adults. Am J Clin Pathol (1985) 0.89
Regional lymphadenectomy and tumor immunity. Surg Gynecol Obstet (1976) 0.89
Early prostate cancer: prevention, treatment modalities, and quality of life issues. Eur Urol (2003) 0.89
Side effects associated with intravesical mitomycin. J Urol (1981) 0.89
Incidence of Pneumocystis carinii antigenemia in ambulatory cancer patients. Cancer (1984) 0.89
Radical cystectomy and adjuvant chemotherapy. Urology (1985) 0.89
Cis-diamminedichloroplatinum II in advanced urothelial cancer. J Urol (1978) 0.89
Bladder neck preservation following radical prostatectomy: continence and margins. Eur Urol (1995) 0.89
Cis-diamminedichloroplatinum (II) in locally advanced and metastatic urothelial cancer. Cancer (1981) 0.89
Urothelial susceptibility to tumor cell implantation: comparison of cauterization with N-methyl-N-nitrosourea. Urology (1983) 0.88